Peginterferon alfa-2a (40KD) (Pegasys®) for the treatment of patients with chronic hepatitis C

International Journal of Clinical Practice

Volumn 57, Issue 7, 2003, Pages 610-615

  Ferenci, Peter ^a  

^a Clinic of Internal Medicine IV   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2A INTERFERON; ALPHA2B INTERFERON; AMANTADINE; INTERFERON; MACROGOL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; THYMOSIN ALPHA1; VIRUS RNA;

ARTICLE; CLINICAL TRIAL; DEPRESSION; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG USE; FEVER; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; MONOTHERAPY; MYALGIA; NEUTROPENIA; PRIORITY JOURNAL; QUALITY OF LIFE; THROMBOCYTOPENIA; VIRUS LOAD;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; POLYETHYLENE GLYCOLS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 0141502388     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Reddy KR, Modi M, Pedder S. Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C. Adv Drug Deliv Rev 2002; 54: 571-586.
2. Wills RJ, Dennis S, Spiegel HE et al. Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection. Clin Pharmacol Ther 1984; 35(5): 722-727.
3. Kozlowski A, Charles SA, Harris JM. Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs 2001; 15(7): 419-429.
4. Roche, UK. Pegasys solution for injection: summary of product characteristics, 2002.
5. Perry CM, Jarvis B. Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C. Drugs 2001; 61(15): 2263-2288.
6. Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alfa therapy. Science 1998; 282: 103-107.
7. Zeuzem S, Herrmann E, Lee JH et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha 2a. Gastroenterology 2001; 120(6): 1438-1447.
8. Jessner W, Stauber R, Hackl F et al. Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection. J Viral Hepat 2003; 10(1): 37-42.
9. Buti M, Sanchez-Avila F, Lurie Y et al. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with two different doses of peginterferon alfa-2b plus ribavirin. Hepatology 2002; 35(4): 930-936.
10. Reddy KR, Wright TL, Pockros PJ et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in non-cirrhotic patients with chronic hepatitis C. Hepatology 2001; 33(2): 433-438.
11. Zeuzem S, Feinman SV, Rasenack J et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-1672.
12. Heathcote EJ, Shiffman ML, Cooksley WG et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673-1680.
13. Hadziyannis SJ, Cheinquer H, Morgan T et al. Peginterferon alfa-2a (40KD) (Pegasys) in combiantion with ribavirin (RBV): efficacy and safety results from a phase III randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose. J Hepatol 2002; 36(suppl 1): 3. Abstract 1.
14. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
15. National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C: 2002. Hepatology 2002; 36(5 suppl 1): S3-S20.
16. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
17. Koff RS. Impaired health-related quality of life in chronic hepatitis C: the how, but not the why. Hepatology 1999; 29(1): 277-279.
18. McHutchison JG, Ware JE, Jr., Bayliss MS et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001; 34(1): 140-147.
19. Ware JE Jr, Bayliss MS, Mannocchia M, Davis GL. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. Interventional Therapy Group. Hepatology 1999; 30(2): 550-555.
20. Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Consensus Interferon Study Group. Hepatology 1999; 29(1): 264-270.
21. Rasenack J, Zeuzem S, Feinman SV et al. Peginterferon alpha-2a (40kD) (Pegasys®) improves HR-QOL outcomes compared with unmodified interferon alpha-2a (Rofero®-A) in patients with chronic hepatitis C. Pharmacoeconomics 2003; 21(5): 341-349.
22. Bernstein D, Kleinman L, Barker CM et al. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002; 35(3): 704-708.
23. Shiffman M. Retreatment of interferon and interferon-ribavirin nonresponders with peginterferon-alpha-2a and ribavirin: initial results from the lead-in phase of the HALT-C trial. Hepatology 2001; 34(4, Pt. 2): 243A. Abstract 79.
24. Shiffman M, investigators. Retreatment of HCV non-responders with peginterferon and ribavirin: results from the lead-in phase of the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology 2002; 36(4, Pt. 2): 295A. Abstract 527.
25. Soriano V, Sulkowski M, Bergin C et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV international panel. Aids 2002; 16(6): 813-828.
26. Iftikar R, Di Bisceglie AM, Pockros P et al. HCV RNA and immunological responses to thymalfasin in combination with peginterferon alfa-2a in HCV non-responders: a 12-week kinetic study. Hepatology 2002; 36(4 pt 2): 360A. Abstract 790.
27. Ferenci P, Gschwantler M, Laferl H et al. Prospective evaluation of the 24 hour interferon-induced decline in hepatitis C virus genotype 1 load to predict response to peginterferon-alfa2a/ribavirin combination therapy. Gastroenterology 2003: Abstract.
28. Schering Plough Europe. PegIntron powder and solvent for solution for injection. Summary of product characteristics, 2000.
29. Manzarbeitia C, Tepermann L, Chalasani N et al. 40 kDa peginterferon alfa-2a (Pegasys®) as a prophylaxis against hepatitis C infection recurrence after liver transplantation (LT): preliminary results of a randomized multicenter trial. Hepatology 2001; 34 (pt 2): 406A. Abstract 938.
30. Vogel W, Ferenci P, Fontana R et al. Peginterferon alfa-2a (40 kDa) (Pegasys®) in liver transplant recipients with established recurrent hepatitis C: interim results of an ongoing randomized multicenter trial. Hepatology 2002; 36 (pt 2): 312A. Abstract 596
31. Goncales F, Bernstein DE, Berg C et al. Peginterferon alfa-2a (40kd) (Pegasys®) plus ribavirin in chronic hepatitis C: retreatment of patients who relapsed virologically after 24 weeks of therapy. Hepatology 2002; 36(pt 2): 361A. Abstract 794.
32. Afdhal N, Flamm S, Imperial JC et al. Analyses of 40 kDa peginterferon alfa-2a (Pegasys®) in combination with ribavirin, mycophenolate mofetil, amantadine or amantadine plus ribavirin in patients that relapsed or did not respond to rebetron therapy: a report of two randomized, multicenter, efficacy and safety studies. Hepatology 2001; 34(pt 2): 243A. Abstract 277.